Oral Therapy Treats Cancer by Suppressing the RAGE Receptor with Dr. Steve Marcus Cantex Pharmaceuticals TRANSCRIPT
Download PDFMay 22, 2023
Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, is developing drugs based on Azeliragon that might slow the metastasis of cancer and extend the survival rate for patients with brain and other cancers. This drug has been shown to suppress the RAGE receptor, which is expressed on the surface of cancer cells and some...
May 22, 2023
Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, is developing drugs based on Azeliragon that might slow the metastasis of cancer and extend the survival rate for patients with brain and other cancers. This drug has been shown to suppress the RAGE receptor, which is expressed on the surface of cancer cells and some...
Engineering Plant Toxin to Cause Tumors to Self-Destruct with Dr. Joshua Schiffman Peel Therapeutics TRANSCRIPT
Download PDFApr 19, 2023
Dr. Joshua Schiffman is the CEO and Co-Founder of Peel Therapeutics and has taken the understanding of the natural resistance to cancer by elephants to develop PEEL-224 to attack tumors. Using a plant toxin and modifying existing approaches, Peel has created a drug that increases the amount of the drug that gets to the...
Engineering Plant Toxin to Cause Tumors to Self-Destruct with Dr. Joshua Schiffman Peel Therapeutics
Apr 19, 2023
Dr. Joshua Schiffman is the CEO and Co-Founder of Peel Therapeutics and has taken the understanding of the natural resistance to cancer by elephants to develop PEEL-224 to attack tumors. Using a plant toxin and modifying existing approaches, Peel has created a drug that increases the amount of the drug that gets to the...
New Treatments for CTCL a Rare Form of Non-Hodgkin Lymphoma with Dr. Myron Czuczman Citius Pharmaceuticals TRANSCRIPT
Download PDFApr 11, 2023
Dr. Myron Czuczman is the Chief Medical Officer and Executive Vice President of Citius Pharmaceuticals, which is developing an advanced treatment for cutaneous T cell lymphoma, CTCL, a rare form of non-Hodgkin lymphoma. The original version of their drug ONTAK has been reformulated, and I/ONTAK is now in clinical...